

ARTICLE 8

CONTROLLED SUBSTANCES

103.22

103.23

103.24 Section 1. Minnesota Statutes 2016, section 152.02, subdivision 2, is amended to read:

103.25 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

103.26 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
103.27 following substances, including their analogs, isomers, esters, ethers, salts, and salts of
103.28 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,
103.29 and salts is possible:

103.30 (1) acetylmethadol;

104.1 (2) allylprodine;

104.2 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
104.3 acetate);

104.4 (4) alphameprodine;

104.5 (5) alphasmethadol;

104.6 (6) alpha-methylfentanyl benzethidine;

104.7 (7) betacetylmethadol;

104.8 (8) betameprodine;

104.9 (9) betamethadol;

104.10 (10) betaprodine;

104.11 (11) clonitazene;

104.12 (12) dextromoramide;

104.13 (13) diampromide;

104.14 (14) diethylambutene;

- 104.15 (15) difenoxin;
- 104.16 (16) dimenoxadol;
- 104.17 (17) dimepheptanol;
- 104.18 (18) dimethylambutene;
- 104.19 (19) dioxaphetyl butyrate;
- 104.20 (20) dipipanone;
- 104.21 (21) ethylmethylthiambutene;
- 104.22 (22) etonitazene;
- 104.23 (23) etoxeridine;
- 104.24 (24) furethidine;
- 104.25 (25) hydroxypethidine;
- 104.26 (26) ketobemidone;
- 104.27 (27) levomoramide;
- 105.1 (28) levophenacymorphan;
- 105.2 (29) 3-methylfentanyl;
- 105.3 (30) acetyl-alpha-methylfentanyl;
- 105.4 (31) alpha-methylthiofentanyl;
- 105.5 (32) benzylfentanyl beta-hydroxyfentanyl;
- 105.6 (33) beta-hydroxy-3-methylfentanyl;
- 105.7 (34) 3-methylthiofentanyl;

- 105.8 (35) thenylfentanyl;
- 105.9 (36) thiofentanyl;
- 105.10 (37) para-fluorofentanyl;
- 105.11 (38) morpheridine;
- 105.12 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 105.13 (40) noracymethadol;
- 105.14 (41) norlevorphanol;
- 105.15 (42) normethadone;
- 105.16 (43) norpipanone;
- 105.17 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 105.18 (45) phenadoxone;
- 105.19 (46) phenampromide;
- 105.20 (47) phenomorphan;
- 105.21 (48) phenoperidine;
- 105.22 (49) piritramide;
- 105.23 (50) proheptazine;
- 105.24 (51) properidine;
- 105.25 (52) propiram;
- 105.26 (53) racemoramide;
- 105.27 (54) tilidine;

- 106.1 (55) trimeperidine;
- 106.2 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
- 106.3 (57)
- 106.4 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide(U47700);
- 106.5 and
- 106.6 (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl).
- 106.7 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
- 106.8 and salts of isomers, unless specifically excepted or unless listed in another schedule,
- 106.9 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
- 106.10 (1) acetorphine;
- 106.11 (2) acetyldihydrocodeine;
- 106.12 (3) benzylmorphine;
- 106.13 (4) codeine methylbromide;
- 106.14 (5) codeine-n-oxide;
- 106.15 (6) cyprenorphine;
- 106.16 (7) desomorphine;
- 106.17 (8) dihydromorphine;
- 106.18 (9) drotebanol;
- 106.19 (10) etorphine;
- 106.20 (11) heroin;
- 106.21 (12) hydromorphinol;
- 106.22 (13) methyl-desorphine;
- 106.23 (14) methyldihydromorphine;

106.24 (15) morphine methylbromide;

106.25 (16) morphine methylsulfonate;

106.26 (17) morphine-n-oxide;

106.27 (18) myrophine;

106.28 (19) nicocodeine;

107.1 (20) nicomorphine;

107.2 (21) normorphine;

107.3 (22) pholcodine; and

107.4 (23) thebacon.

107.5 (d) Hallucinogens. Any material, compound, mixture or preparation which contains any
107.6 quantity of the following substances, their analogs, salts, isomers (whether optical, positional,
107.7 or geometric), and salts of isomers, unless specifically excepted or unless listed in another
107.8 schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
107.9 possible:

107.10 (1) methylenedioxy amphetamine;

107.11 (2) methylenedioxymethamphetamine;

107.12 (3) methylenedioxy-N-ethylamphetamine (MDEA);

107.13 (4) n-hydroxy-methylenedioxyamphetamine;

107.14 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);

107.15 (6) 2,5-dimethoxyamphetamine (2,5-DMA);

107.16 (7) 4-methoxyamphetamine;

107.17 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;

107.18 (9) alpha-ethyltryptamine;

- 107.19 (10) bufotenine;
- 107.20 (11) diethyltryptamine;
- 107.21 (12) dimethyltryptamine;
- 107.22 (13) 3,4,5-trimethoxyamphetamine;
- 107.23 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- 107.24 (15) ibogaine;
- 107.25 (16) lysergic acid diethylamide (LSD);
- 107.26 (17) mescaline;
- 107.27 (18) parahexyl;
- 107.28 (19) N-ethyl-3-piperidyl benzilate;
- 108.1 (20) N-methyl-3-piperidyl benzilate;
- 108.2 (21) psilocybin;
- 108.3 (22) psilocyn;
- 108.4 (23) tenocyclidine (TCP or TCP);
- 108.5 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- 108.6 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
- 108.7 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- 108.8 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- 108.9 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- 108.10 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);

- 108.11 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- 108.12 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- 108.13 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- 108.14 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
- 108.15 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 108.16 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
- 108.17 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 108.18 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 108.19 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
108.20 (2-CB-FLY);
- 108.21 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 108.22 (40) alpha-methyltryptamine (AMT);
- 108.23 (41) N,N-diisopropyltryptamine (DiPT);
- 108.24 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 108.25 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 108.26 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
- 108.27 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 109.1 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 109.2 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 109.3 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 109.4 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);

- 109.5 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 109.6 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
- 109.7 (52) ~~5-methoxy-N-methyl-N-propyltryptamine~~
- 109.8 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
- 109.9 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
- 109.10 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 109.11 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 109.12 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 109.13 (57) methoxetamine (MXE);
- 109.14 (58) 5-iodo-2-aminoindane (5-IAI);
- 109.15 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 109.16 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
- 109.17 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
- 109.18 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
- 109.19 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 109.20 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
- 109.21 (65) N,N-Dipropyltryptamine (DPT);
- 109.22 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
- 109.23 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
- 109.24 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
- 109.25 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);

109.26 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylorketamine,
109.27 ethketamine, NENK); ~~and~~

109.28 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);

110.1 (72) 3-(2-Ethyl(methylaminoethyl)-1H-indol-4-yl (4-AcO-MET); and

110.2 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).

110.3 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*
110.4 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
110.5 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
110.6 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
110.7 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
110.8 Church, and members of the American Indian Church are exempt from registration. Any
110.9 person who manufactures peyote for or distributes peyote to the American Indian Church,
110.10 however, is required to obtain federal registration annually and to comply with all other
110.11 requirements of law.

110.12 (f) Central nervous system depressants. Unless specifically excepted or unless listed in
110.13 another schedule, any material compound, mixture, or preparation which contains any
110.14 quantity of the following substances, their analogs, salts, isomers, and salts of isomers
110.15 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

110.16 (1) mecloqualone;

110.17 (2) methaqualone;

110.18 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;

110.19 (4) flunitrazepam; and

110.20 (5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
110.21 methoxyketamine).

110.22 (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
110.23 material compound, mixture, or preparation which contains any quantity of the following
110.24 substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the
110.25 analogs, salts, isomers, and salts of isomers is possible:

110.26 (1) aminorex;

- 110.27 (2) cathinone;
- 110.28 (3) fenethylamine;
- 110.29 (4) methcathinone;
- 110.30 (5) methylaminorex;
- 110.31 (6) N,N-dimethylamphetamine;
- 111.1 (7) N-benzylpiperazine (BZP);
- 111.2 (8) methylmethcathinone (mephedrone);
- 111.3 (9) 3,4-methylenedioxy-N-methylcathinone (methylone);
- 111.4 (10) methoxymethcathinone (methedrone);
- 111.5 (11) methylenedioxypropylamphetamine (MDPV);
- 111.6 (12) 3-fluoro-N-methylcathinone (3-FMC);
- 111.7 (13) methylethcathinone (MEC);
- 111.8 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
- 111.9 (15) dimethylmethcathinone (DMMC);
- 111.10 (16) fluoroamphetamine;
- 111.11 (17) fluoromethamphetamine;
- 111.12 (18) α -methylaminobutyrophenone (MABP or buphedrone);
- 111.13 (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
- 111.14 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
- 111.15 (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
111.16 naphyrone);

- 111.17 (22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
- 111.18 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
- 111.19 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
- 111.20 (25) 4-methyl-N-ethylcathinone (4-MEC);
- 111.21 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
- 111.22 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 111.23 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
- 111.24 (29) 4-fluoro-N-methylcathinone (4-FMC);
- 111.25 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
- 111.26 (31) alpha-pyrrolidinobutiophenone (α -PBP);
- 111.27 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
- 112.1 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
- 112.2 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); ~~and~~
- 112.3 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
- 112.4 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4-chloro-PPP);
- 112.5 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
- 112.6 and
- 112.7 (38) any other substance, except bupropion or compounds listed under a different
- 112.8 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
- 112.9 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
- 112.10 compound is further modified in any of the following ways:
- 112.11 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
- 112.12 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
- 112.13 system by one or more other univalent substituents;

- 112.14 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
- 112.15 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
112.16 methoxybenzyl groups; or
- 112.17 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
- 112.18 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
112.19 excepted or unless listed in another schedule, any natural or synthetic material, compound,
112.20 mixture, or preparation that contains any quantity of the following substances, their analogs,
112.21 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
112.22 of the isomers, esters, ethers, or salts is possible:
- 112.23 (1) marijuana;
- 112.24 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic
112.25 equivalents of the substances contained in the cannabis plant or in the resinous extractives
112.26 of the plant, or synthetic substances with similar chemical structure and pharmacological
112.27 activity to those substances contained in the plant or resinous extract, including, but not
112.28 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
112.29 cis or trans tetrahydrocannabinol;
- 112.30 (3) synthetic cannabinoids, including the following substances:
- 113.1 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
113.2 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
113.3 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
113.4 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
113.5 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
113.6 naphthoylindoles include, but are not limited to:
- 113.7 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
- 113.8 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
- 113.9 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
- 113.10 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
- 113.11 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

- 113.12 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
- 113.13 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
- 113.14 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
- 113.15 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
- 113.16 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
- 113.17 (ii) Naphthylmethylindoles, which are any compounds containing a
113.18 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
113.19 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
113.20 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
113.21 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
113.22 ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
- 113.23 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
- 113.24 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
- 113.25 (iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
113.26 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
113.27 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
113.28 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
113.29 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
113.30 naphthoylpyrroles include, but are not limited to,
113.31 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
- 114.1 (iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene
114.2 structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
114.3 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
114.4 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any
114.5 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
114.6 naphthylmethylindenes include, but are not limited to,
114.7 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
- 114.8 (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
114.9 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
114.10 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
114.11 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any

- 114.12 extent, whether or not substituted in the phenyl ring to any extent. Examples of
114.13 phenylacetylindoles include, but are not limited to:
- 114.14 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
- 114.15 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
- 114.16 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
- 114.17 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
- 114.18 (vi) Cyclohexylphenols, which are compounds containing a
114.19 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
114.20 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
114.21 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
114.22 in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
114.23 limited to:
- 114.24 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
- 114.25 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
114.26 (Cannabicyclohexanol or CP 47,497 C8 homologue);
- 114.27 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
114.28 -phenol (CP 55,940).
- 114.29 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
114.30 with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
114.31 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
114.32 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
115.1 extent and whether or not substituted in the phenyl ring to any extent. Examples of
115.2 benzoylindoles include, but are not limited to:
- 115.3 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
- 115.4 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
- 115.5 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
115.6 48,098 or Pravadoline).
- 115.7 (viii) Others specifically named:

- 115.8 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
115.9 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
- 115.10 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
115.11 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
- 115.12 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
115.13 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
- 115.14 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
- 115.15 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
115.16 (XLR-11);
- 115.17 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
115.18 (AKB-48(APINACA));
- 115.19 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
115.20 (5-Fluoro-AKB-48);
- 115.21 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
- 115.22 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
- 115.23 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
115.24 (AB-PINACA);
- 115.25 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
115.26 1H-indazole-3-carboxamide (AB-FUBINACA);
- 115.27 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
115.28 indazole-3-carboxamide(AB-CHMINACA);
- 115.29 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
115.30 (5-fluoro-AMB);
- 116.1 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 116.2 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
116.3 (FUBIMINA);

- 116.4 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
116.5 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 116.6 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
116.7 -1H-indole-3-carboxamide (5-fluoro-ABICA);
- 116.8 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
116.9 -1H-indole-3-carboxamide;
- 116.10 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
116.11 -1H-indazole-3-carboxamide;
- 116.12 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
- 116.13 (U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
116.14 H-indazole-3-carboxamide (MAB-CHMINACA);
- 116.15 (V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
116.16 (ADB-PINACA);
- 116.17 (W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
- 116.18 (X)
116.19 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide.
- 116.20 (APP-CHMINACA); ~~and~~
- 116.21 (Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
- 116.22 (Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
- 116.23 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
116.24 for human consumption.
- 116.25 Sec. 2. Minnesota Statutes 2016, section 152.02, subdivision 12, is amended to read:
- 116.26 Subd. 12. **Coordination of controlled substance regulation with federal law and**
116.27 **state statute.** If any substance is designated, rescheduled, or deleted as a controlled substance
116.28 under federal law and notice thereof is given to the state Board of Pharmacy, the state Board
116.29 of Pharmacy shall similarly control the substance under this chapter, after the expiration of
116.30 30 days from publication in the Federal Register of a final order designating a substance as
116.31 a controlled substance or rescheduling or deleting a substance. Such order shall be filed

117.1 ~~with the secretary of state. If within that 30-day period, the state Board of Pharmacy objects~~
117.2 ~~to inclusion, rescheduling, or deletion, it shall publish the reasons for objection and afford~~
117.3 ~~all interested parties an opportunity to be heard. At the conclusion of the hearing, the state~~
117.4 ~~Board of Pharmacy shall publish its decision, which shall be subject to the provisions of~~
117.5 ~~chapter 14, the substance shall be deemed to be similarly designated, rescheduled, or deleted~~
117.6 ~~under this section until the legislature enacts legislation or the board engages in rulemaking~~
117.7 ~~to otherwise schedule the drug.~~

117.8 In exercising the authority granted by this chapter, the state Board of Pharmacy shall be
117.9 subject to the provisions of chapter 14.

117.10 The state Board of Pharmacy shall annually submit a report to the legislature on or before
117.11 December 1 that specifies what changes the board made to the controlled substance schedules
117.12 maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in the preceding
117.13 12 months. The report must include specific recommendations for amending the controlled
117.14 substance schedules contained in subdivisions 2 to 6, so that they conform with the controlled
117.15 substance schedules maintained by the board in Minnesota Rules, parts 6800.4210 to
117.16 6800.4250.